The conversation about psychedelics in mental health care has been building for years—but a federal executive order signals something different. It suggests that what was once considered fringe is now being taken seriously at the highest levels of government.
Last week, President Donald Trump signed an executive order directing federal health agencies to expand access to psychedelic therapies.
While policy details matter, the broader implication is clear: there is growing recognition that current approaches to treating depression, PTSD, and other mental health conditions are insufficient—and that new tools, including psychedelic-assisted therapies, may help address these unmet needs.
What the Executive Order Signals
An executive order like this is less about immediate clinical change and more about direction and prioritization. It signals federal willingness to invest in and explore alternatives to traditional psychiatric care, particularly for populations that have not responded to standard treatments.
In practical terms, this likely means increased support for research, greater coordination among agencies such as the FDA and NIH, and a push to better understand how these therapies could be safely integrated into mainstream care. It may also help accelerate regulatory pathways, which have historically been slow for novel treatments.
For clinicians and patients, this shift matters. It legitimizes a category of treatments that many have already seen work firsthand but that have existed in a regulatory gray zone.
Why This Moment Is Significant
Mental health care is at an inflection point. Traditional treatments—primarily SSRIs, SNRIs, and psychotherapy—remain foundational, but they don’t work for everyone. A meaningful share of patients continue to struggle despite multiple medication trials, often for years.
Psychedelic therapies offer a fundamentally different model. Rather than relying on daily medications that gradually modulate neurotransmitters, these treatments are typically episodic, experience-based, and tied to neuroplasticity. In some cases, patients report meaningful improvements within hours or days, rather than weeks.
The executive order underscores a growing openness to this model, particularly for conditions like treatment-resistant depression and PTSD, where the need for better options is urgent.
The Reality: Challenges Still Exist
As promising as this space is, there are real limitations that shouldn’t be overlooked.
One of the biggest barriers is accessibility. Many psychedelic therapies are resource-intensive by design. A typical session with substances like psilocybin or MDMA may last most of the day and require multiple trained providers. When you factor in preparation and integration sessions, the cost can quickly become prohibitive for many patients.
There’s also the issue of workforce capacity. These therapies depend heavily on skilled therapeutic support, and there simply aren’t enough trained clinicians to meet potential demand. Scaling this model will take time, training infrastructure, and thoughtful regulation.
Safety is another important consideration—and it varies significantly by substance. For example, ibogaine has gained attention for its potential role in treating addiction, but it carries a known risk of cardiac toxicity, including QT prolongation and torsades de pointes. This makes proper screening and monitoring essential. Other compounds, like MDMA and psilocybin, may be physiologically safer in controlled settings but still require careful psychological support to minimize the risk of distressing or destabilizing experiences.
Where Ketamine Fits In
As awareness of psychedelic therapies grows, many patients will begin exploring their options. For most, the first realistic and accessible entry point will be ketamine.
Unlike other psychedelics, ketamine is already used in clinical practice. It has an FDA-approved form—Spravato—and is also widely administered off-label via IV and IM. This gives it a unique position in the current landscape: it’s both innovative and established.
Why Ketamine Stands Out
One of ketamine’s biggest advantages is its safety profile when used appropriately. In a monitored medical setting, it carries fewer cardiac risks than ibogaine and doesn’t require the prolonged physiological strain of an all-day session. Dosing can be adjusted in real time, especially with IV administration, allowing for a more controlled, individualized experience.
It’s also known for its rapid onset. Many patients experience a noticeable shift in mood or a reduction in suicidal thoughts within hours to days. For individuals who have spent years trying different medications without success, this can be a meaningful and sometimes life-saving change.
From a practical standpoint, ketamine is more accessible. Treatments are relatively short—typically under an hour for the infusion itself—and don’t require the same full-day commitment as other psychedelic therapies. This makes it more feasible for patients balancing work, family, and other responsibilities.
There’s also built-in oversight, particularly with esketamine. The FDA’s REMS program requires in-clinic administration and post-treatment monitoring, which helps reduce the risk of misuse while maintaining patient safety.
Finally, ketamine is backed by a substantial and growing body of research. While studies on other psychedelics are ongoing and promising, ketamine currently has one of the most robust evidence bases in this category, especially for real-world clinical use.
What This Means Going Forward
The executive order doesn’t immediately change what’s available to patients, but it accelerates a broader shift in how we think about mental health treatment.
As research expands and regulatory pathways evolve, we’re likely to see more options come online. At the same time, increased awareness will prompt more patients to seek treatments that are already available and supported by evidence.
For many, that will mean discovering ketamine.
A Balanced Perspective
It’s easy to view psychedelics in extremes—as either breakthrough cures or risky, unproven therapies. The truth lies somewhere in the middle.
These treatments mark a meaningful shift in how we approach mental health, particularly for those who haven’t responded to traditional care. But they also require careful implementation, appropriate safeguards, and a commitment to patient-centered care.
Ketamine, in many ways, serves as a bridge. It offers access to many of the benefits associated with this new wave of treatments—rapid relief, enhanced neuroplasticity, and a different therapeutic framework—while maintaining a strong foundation of safety and clinical experience.
As policy continues to evolve, the goal should remain the same: expanding access to treatments that are not only innovative but also safe, effective, and grounded in real-world care.
References:
“Fact Sheet: President Donald J. Trump Is Accelerating Medical Treatments for Serious Mental Illness.” The White House, 18 Apr. 2026, White House Fact Sheet.
“Accelerating Medical Treatments for Serious Mental Illness.” The White House, 18 Apr. 2026, White House Presidential Action.
Greenwood, Veronique. “What to Know About Trump’s Psychedelics Executive Order.” Time, 21 Apr. 2026, TIME article on Trump psychedelics executive order.
About the Author
Dr. Rivas is a ketamine specialist and board-certified acute care and trauma surgeon with over 12 years of experience in ketamine administration. Before founding Innerbloom Ketamine Therapy in 2022, Dr. Rivas served on the frontlines of emergency and trauma medicine in Santa Maria, CA, and Austin, TX. Dr. Rivas applies his extensive medical expertise to provide safe, evidence-based ketamine treatments for mood disorders, including depression, anxiety, PTSD, and chronic pain. His passion lies in helping patients find relief and rediscover hope through personalized, compassionate care.
Newy: Bridging the Gap Between Ketamine Treatment and Everyday Wellness
A supplement formulated by Dr. Rivas for enhanced brain and mood support. The formula pairs especially well with ketamine therapy by helping extend and enhance the neuroplasticity effects. That said, the ingredients are equally effective on their own, so it’s a supportive option whether or not someone is undergoing ketamine treatment. Learn more about how Newy supports cognitive function detoxification and cellular repair.
Medical Disclaimer
All content on this website, including but not limited to this article, blog posts, testimonials, and FAQs, is not medical advice and should not be considered as such. This website cannot diagnose or treat any medical condition. Only a licensed medical professional who is familiar with you and your medical history can provide medical advice, diagnosis, or treatment.
The information provided here is for educational and informational purposes only. It is not intended to replace a consultation with a qualified healthcare provider. If you are experiencing symptoms of depression or any mental health condition, please consult with a licensed mental health professional or your primary care physician.
If you are in crisis or experiencing suicidal thoughts, please call the 988 Suicide and Crisis Lifeline (call or text 988) or go to your nearest emergency room immediately.
Innerbloom Ketamine Therapy cannot be held responsible or liable for any actions taken by those who access our website or rely on its content. Please refer to our Terms & Conditions for more information.
Struggling with depression that won’t respond to traditional treatments? Contact Innerbloom Ketamine Therapy at (805) 321-8471 or visit us at 100 Casa Street, Suite D3, San Luis Obispo, CA 93405.